The role of biologics in the treatment of giant cell arteritis

References

• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–1461.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261–271.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine. 2007;86:61–68.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50–57.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA. The diagnosis and management of patients with giant cell arteritis. J Rheumatol. 2005;32:1186–1188.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep. 2015;17:6.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Castañeda S, Giant Cell LJ. Arteritis: visual loss is our major concern. J Rheumatol. 2016;43:1458–1461.
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3522–3531.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine. 2004;83:335–341.
   PubMed Web of Science ®Google Scholar
• García-Martínez A, Arguis P, Prieto-González S, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2014;73:1826–1832.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet. 2017;390(10103):1700–1712.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine. 2009;88:227–235.
   PubMed Web of Science ®Google Scholar
• Prior JA, Ranjbar H, Belcher J, et al. Diagnostic delay for giant cell arteritis – a systematic review and meta-analysis. BMC Med. 2017;15:120.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Giant Cell Arteritis Guideline Development Group. Concise guidance: diagnosis and management of giant cell arteritis. Clin Med (Lond). 2010;10:381–386.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine. 2005;84:277–290.
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703–708.
   PubMed Web of Science ®Google Scholar
• Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine. 2011;90:186–193.
   PubMed Web of Science ®Google Scholar
• Roncato C, Allix-Béguec C, Brottier-Mancini E, et al. Diagnostic performance of colour duplex ultrasonography along with temporal artery biopsy in suspicion of giant cell arteritis. Clin Exp Rheumatol. 2017;35(Suppl 103):119–122.
   PubMedGoogle Scholar
• Dejaco C, Ramiro S, Duftner C et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77:636–643.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-19–31.
   Web of Science ®Google Scholar
• Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–317.
   PubMed Web of Science ®Google Scholar
• Yates M, Loke YK, Watts RA, et al. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol. 2014;33:227–236.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Pina T, Prieto-Peña D, et al. Current and emerging diagnosis tools and therapeutics for giant cell arteritis. Expert Rev Clin Immunol. 2018;14:593–605.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484–491.
   PubMed Web of Science ®Google Scholar
• Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNF-alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology. 2004;43:294–301.
   PubMed Web of Science ®Google Scholar
• Field M, Cook A, Gallagher G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int. 1997;17:113–118.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–630.
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomized controlled trial. Ann Rheum Dis. 2014;73:2074–2081.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625–630.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Schonberger J, Oppitz U, et al. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med. 1994;179:951–960.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest. 1994;94:1134–1140.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res. 2010;62:835–841.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29:456–458.
   PubMedGoogle Scholar
• Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol. 2013;25:3–9.
   PubMed Web of Science ®Google Scholar
• Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology. 2012;51:151–156.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44:717–723.
   PubMed Web of Science ®Google Scholar
• Régent A, Redeker S, Deroux A, et al. Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients. J Rheumatol. 2016;43:1547–1552.
   PubMed Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–1927.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant cell arteritis. N Engl J Med. 2017;377:317–328.
   PubMed Web of Science ®Google Scholar
• Calderon-Goercke M, Loricera J, Prieto-Peña D, et al. Tocilizumab in giant cell arteritis. National multicenter study of 134 patients of clinical practice. Abstract supplement 2018 ACR/ARHP annual meeting. Arthritis Rheumatol. 2018;70(Suppl 9):Abstract Number 2752.
   Google Scholar
• Prieto-Peña D, Loricera J, Calderon-Goercke M, et al. Giant cell arteritis in treatment with tocilizumab. evolution of vascular fdg uptake on PET/CT. Abstract supplement 2018 ACR/ARHP annual meeting. Arthritis Rheumatol. 2018;70(Suppl 9):Abstract Number 2748.
   Google Scholar
• Loricera J, Blanco R, Castañeda S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol. 2014;32(3 Suppl. 82):S79–89.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S44–53.
   PubMed Web of Science ®Google Scholar
• Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol. 2014;66:768–769.
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69:837–845.
   PubMed Web of Science ®Google Scholar
• De Boysson H, Aouba A. Abatacept as adjunctive therapy for the treatment of giant cell arteritis: comment on the article by Langford et al.. Arthritis Rheumatol. 2017;69:1504.
   PubMed Web of Science ®Google Scholar
• Samson M, Ghesquière T, Berthier S, et al. Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis. Ann Rheum Dis. 2018;77:e6.
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, O’Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75:1578–1579.
   PubMed Web of Science ®Google Scholar
• Ly KH, Stirnemann J, Liozon E, et al. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. 2014;81:76–78.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521–546.
   PubMed Web of Science ®Google Scholar
• Hartmann B, Liao J, Weisman MH, et al. The STAT1 signaling pathway in giant cell arteritis. 2013 ACR/ARHP annual meeting; 2013; Abstract Number: 1691.
   Google Scholar
• Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137:1934–1948.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, et al. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12:436–442.
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497–1504.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789–2797.
   PubMed Web of Science ®Google Scholar
• Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. 2012;64:1720–1729.
   PubMed Web of Science ®Google Scholar
• Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, et al. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum. 2008;38:116–123.
   PubMed Web of Science ®Google Scholar